针对非小细胞肺癌中的RET变化
1Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN, USA.
Current problems in cancer
|March 17, 2024
概括
在转移过程中重新排列 (RET) 变化驱动癌症,特别是非小细胞肺癌 (NSCLC). 虽然RET抑制剂提供了新的治疗方法,但获得的耐药性是一个重大的挑战,需要进一步研究.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 在转移 (RET) 过程中重新排列的原基因变化激活了各种癌症中的瘤性途径.
- 在非小细胞肺癌 (NSCLC) 患者的1-2%中发现了RET融合,导致瘤生长.
- 选择性RET抑制剂 (selpercatinib,pralsetinib) 在2020年FDA批准后彻底改变了NSCLC的治疗方法.
研究的目的:
- 审查NSCLC中RET的生物学.
- 分析NSCLC中RET抑制剂的临床结果.
- 探索克服RET抑制剂耐药性的挑战和未来方向.
主要方法:
- 对RET生物学,测试方法和临床试验数据的文献综述.
- 对目标和目标之外的RET电阻机制的分析.
- 对RET变异性NSCLC的当前和未来治疗策略的综合.
主要成果:
- 第一代RET抑制剂是对RET融合阳性NSCLC的标准护理.
- 对RET抑制剂的获得性耐药性是一个日益增长的临床挑战.
- 了解耐药机制对于开发下一代疗法至关重要.
结论:
- RET的改变是NSCLC的关键目标,抑制剂显示出显著的疗效.
- 克服获得的耐药性对于长期的患者益处至关重要.
- 持续的研究和临床试验对于在NSCLC中推进RET向治疗至关重要.
更多相关视频
11:15Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
24.4K
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
8.0K
相关概念视频
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
The Retinoblastoma Gene
4.1K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.1K
lncRNA - Long Non-coding RNAs
8.6K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.6K
